

ERRATUM

Open Access



Erratum to: PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury

Flora M. Hammond^{1*}, David N. Alexander², Andrew J. Cutler³, Stephen D'Amico⁴, Rachelle S. Doody⁵, William Sauve⁶, Richard D. Zorowitz⁷, Charles S. Davis⁸, Paul Shin⁹, Fred Ledon⁹, Charles Yonan⁹, Andrea E. Formella⁹ and Joao Siffert⁹

Erratum

After publication of the original article [1], the authors noticed that there were errors in the caption of Fig. 3, and the y-axis of Fig. 6 itself.

The following statement should not have been included in the caption of Fig. 3: "CNS-LS scores were not normalized." The CNS-LS is a rank-order scale, and is not normalized. This statement was included erroneously and the authors intended on removing it prior to resubmission, but this was unfortunately overlooked.

Similarly, the y-axis within Fig. 6 was mislabelled. The CNS-LS scale ranges from 7 to 35, so the y-axis for Fig. 6 should start at a base score of 7 and not zero. The correct and updated version of Fig. 6, in which the data presented remain accurate and are unchanged, is published in this erratum.

Author details

¹Physical Medicine and Rehabilitation, Indiana University School of Medicine, Rehabilitation Hospital of Indiana, 4141 Shore Drive, Indianapolis, IN 46254, USA. ²University of California, Los Angeles, CA, USA. ³Florida Clinical Research Center, LLC, Bradenton, FL, USA. ⁴Cornerstone Medical Group, Franklin, TN, USA. ⁵Baylor College of Medicine, Houston, TX, USA. ⁶TMS NeuroHealth Centers, Richmond, VA, USA. ⁷MedStar National Rehabilitation Network, Washington, DC, USA. ⁸CSD Biostatistics, Inc., Tucson, AZ, USA. ⁹Avanir Pharmaceuticals, Inc., Aliso Viejo, CA, USA.

Published online: 02 September 2016


Reference

1. Hammond FM, Alexander DN, Cutler AJ, D'Amico S, Doody RS, Sauve W, et al. PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury. *BMC Neurol.* 2016;16:89. doi:10.1186/s12883-016-0609-0.

* Correspondence: Flora.hammond@rhin.com

¹Physical Medicine and Rehabilitation, Indiana University School of Medicine, Rehabilitation Hospital of Indiana, 4141 Shore Drive, Indianapolis, IN 46254, USA

PRISM II: Mean CNS-LS Scores Across DM/Q Studies for PBA in Diverse Neurologic Conditions



*DM/Q 30/30 mg twice daily; this dose is not FDA-approved; [†]DM/Q 20/10 mg twice daily. [‡]Improvement from baseline in mean CNS-LS (SE).

99-AVR-102 (4 week study): End of study= mean of CNS-LS scores for Days 15 and 29; $P=0.001$ vs. controls.

02-AVR-106 (12 week DBPC study): End of study= mean of CNS-LS scores on Days 15, 29, 57, and 85; $P<0.0001$ vs. placebo.

07-AVR-123 (12 week DBPC study): End of study is Week 12 intent to treat; $P<0.05$ vs. placebo.

PRISM II: End of study is at Day 90/Final Visit; $P<0.001$ vs. baseline

Fig. 6 Mean CNS-LS Scores Across DM/Q Studies for PBA Secondary to Diverse Neurologic Conditions. *DM/Q 30/30 mg twice daily; [†]DM/Q 20/10 mg twice daily. [‡]Improvement from baseline in mean CNS-LS (SE). 99-AVR-102 (4 week study comparing DM/Q to DM or Q monotherapy): End of study is the mean of the CNS-LS scores for Days 15 and 29; $P=0.001$ vs. dextromethorphan comparator and $P<0.001$ vs. quinidine comparator. 02-AVR-106 (12 week DBPC study): End of study is the mean of the CNS-LS scores on Days 15, 29, 57, and 85; $P<0.0001$ vs. placebo. 07-AVR-123 (12 week DBPC study): End of study is at Week 12 intent to treat; $P<0.05$ vs. placebo. PRISM II: End of study is at Day 90/Final Visit; $P<0.001$ vs. baseline in all 3 cohorts. ALS = amyotrophic lateral sclerosis; CNS-LS = Center for Neurologic Study–Lablity Scale; DM/Q = dextromethorphan/quinidine; MS = multiple sclerosis; PBA = pseudobulbar affect; TBI = traumatic brain injury; SE = standard error